烷基化试剂耐药机制。
Mechanisms of resistance to alkylating agents.
机构信息
Department of Oncology, Instituto di Ricerche Farmacologiche 'Mario Negri', Via Eritrea 62, 20157, Milan, Italy.,
出版信息
Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.
Abstract
Alkylating agents are the most widely used anticancer drugs whose main target is the DNA, although how exactly the DNA lesions cause cell death is still not clear. The emergence of resistance to this class of drugs as well as to other antitumor agents is one of the major causes of failure of cancer treatment. This paper reviews some of the best characterized mechanisms of resistance to alkylating agents. Pre- and post-target mechanisms are recognized, the former able to limit the formation of lethal DNA adducts, and the latter enabling the cell to repair or tolerate the damage. The role in the pre-target mechanisms of reduced drug accumulation and the increased detoxification or activation systems (such as DT-diaphorase, metallothionein, GST/GSH system, etc...) are discussed. In the post-target mechanisms the different DNA repair pathways, tolerance to alkylation damage and the 'downstream' effects (cell cycle arrest and/or apoptosis) are examined.
摘要
烷化剂是应用最广泛的抗癌药物，其主要作用靶点是 DNA，尽管确切的 DNA 损伤如何导致细胞死亡尚不清楚。对这类药物以及其他抗肿瘤药物的耐药性的出现是癌症治疗失败的主要原因之一。本文综述了一些对烷化剂耐药性的特征性机制。目前已经认识到了靶前和靶后机制，前者能够限制致死性 DNA 加合物的形成，后者使细胞能够修复或耐受损伤。本文讨论了药物蓄积减少和解毒或激活系统（如 DT-黄递酶、金属硫蛋白、GST/GSH 系统等）增加在靶前机制中的作用。在后靶机制中，研究了不同的 DNA 修复途径、对烷化损伤的耐受性以及“下游”效应（细胞周期停滞和/或细胞凋亡）。
相似文献
1
Mechanisms of resistance to alkylating agents.烷基化试剂耐药机制。
Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.
2
Activity of quinone alkylating agents in quinone-resistant cells.醌类烷基化剂在耐醌细胞中的活性。
Cancer Res. 1990 May 15;50(10):2872-6.
3
Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.DNA 修复和损伤反应途径对烷化剂非线性遗传毒性反应的贡献。
Mutat Res Rev Mutat Res. 2016 Jan-Mar;767:77-91. doi: 10.1016/j.mrrev.2015.11.001. Epub 2015 Dec 2.
4
Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.基于吲哚和环戊[b]吲哚的氮丙啶基醌类抗肿瘤剂：细胞毒性和抗肿瘤活性的构效关系
J Med Chem. 2001 Oct 25;44(22):3545-62. doi: 10.1021/jm010085u.
5
Alkylation damage in DNA and RNA--repair mechanisms and medical significance.DNA和RNA中的烷基化损伤——修复机制及医学意义
DNA Repair (Amst). 2004 Nov 2;3(11):1389-407. doi: 10.1016/j.dnarep.2004.05.004.
6
On the role of alkylating mechanisms, O-alkylation and DNA-repair in genotoxicity and mutagenicity of alkylating methanesulfonates of widely varying structures in bacterial systems.关于烷基化机制、O-烷基化和DNA修复在细菌系统中结构差异很大的烷基化甲磺酸盐的遗传毒性和诱变性中的作用。
Chem Biol Interact. 2001 Jul 31;137(1):89-99. doi: 10.1016/s0009-2797(01)00211-3.
7
From old alkylating agents to new minor groove binders.从旧的烷化剂到新的小沟结合剂。
Crit Rev Oncol Hematol. 2014 Jan;89(1):43-61. doi: 10.1016/j.critrevonc.2013.07.006. Epub 2013 Aug 20.
8
Mechanisms of chemoresistance to alkylating agents in malignant glioma.恶性胶质瘤对烷化剂化疗耐药的机制
Clin Cancer Res. 2008 May 15;14(10):2900-8. doi: 10.1158/1078-0432.CCR-07-1719.
9
DNA alkylation damage and autophagy induction.DNA 烷基化损伤与自噬诱导。
Mutat Res. 2013 Oct-Dec;753(2):91-99. doi: 10.1016/j.mrrev.2013.07.001. Epub 2013 Jul 18.
10
Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove.随着小沟中序列选择性DNA烷基化增加，DNA修复途径选择发生改变。
Chem Biol. 2000 Sep;7(9):659-68. doi: 10.1016/s1074-5521(00)00010-7.
引用本文的文献
1
Protective Effects of L-Cysteine Against Cisplatin-Induced Oxidative Stress-Mediated Reproductive Damage.L-半胱氨酸对顺铂诱导的氧化应激介导的生殖损伤的保护作用。
Antioxidants (Basel). 2024 Nov 23;13(12):1443. doi: 10.3390/antiox13121443.
2
biofilm in inflammatory breast cancer and its treatment strategies.炎性乳腺癌中的生物膜及其治疗策略。
Biofilm. 2024 Sep 13;8:100220. doi: 10.1016/j.bioflm.2024.100220. eCollection 2024 Dec.
3
Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.取消 G2/M 检查点作为烷化剂的化疗增敏方法。
Neuro Oncol. 2024 Jun 3;26(6):1083-1096. doi: 10.1093/neuonc/noad252.
4
Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation.谷胱甘肽介导的抗癌药物结合：反应机制和药物解毒与生物活化的生物学意义概述。
Molecules. 2022 Aug 17;27(16):5252. doi: 10.3390/molecules27165252.
5
A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy.急性胸腺萎缩与化疗后晚期不良反应之间的关联。
Front Immunol. 2022 Jul 1;13:933547. doi: 10.3389/fimmu.2022.933547. eCollection 2022.
6
Cleavage of Abasic Sites in DNA by an Aminoquinoxaline Compound: Augmented Cytotoxicity and DNA Damage in Combination with an Anticancer Drug Chlorambucil in Human Colorectal Carcinoma Cells.一种氨基喹喔啉化合物对DNA中无碱基位点的切割：在人结肠癌细胞中与抗癌药苯丁酸氮芥联合使用时增强的细胞毒性和DNA损伤。
ACS Omega. 2022 Feb 18;7(8):6488-6501. doi: 10.1021/acsomega.1c04962. eCollection 2022 Mar 1.
7
Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.纳米医学策略在肺癌耐药管理中的应用。
Int J Mol Sci. 2022 Feb 6;23(3):1853. doi: 10.3390/ijms23031853.
8
Novel Marine Secondary Metabolites Worthy of Development as Anticancer Agents: A Review.新型海洋次生代谢产物值得开发为抗癌药物：综述。
Molecules. 2021 Sep 23;26(19):5769. doi: 10.3390/molecules26195769.
9
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.聚（ADP-核糖）聚合酶抑制剂：临床相关性、作用机制及肿瘤耐药性
Front Cell Dev Biol. 2020 Sep 9;8:564601. doi: 10.3389/fcell.2020.564601. eCollection 2020.
10
Combined effects of mesenchymal stem cells carrying cytosine deaminase gene with 5-fluorocytosine and temozolomide in orthotopic glioma model.携带胞嘧啶脱氨酶基因的间充质干细胞联合5-氟胞嘧啶和替莫唑胺在原位胶质瘤模型中的联合效应
Am J Cancer Res. 2020 May 1;10(5):1429-1441. eCollection 2020.
本文引用的文献
1
Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA.铂敏感和铂耐药的卵巢癌组织在p53、ERCC1和XPA的mRNA水平之间的关系上存在差异。
Int J Oncol. 1996 Feb;8(2):313-7. doi: 10.3892/ijo.8.2.313.
2
DNA minor groove binding ligands: a new class of anticancer agents.DNA小沟结合配体：一类新型抗癌剂。
Expert Opin Investig Drugs. 1997 Jul;6(7):875-84. doi: 10.1517/13543784.6.7.875.
3
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
Br J Cancer. 1997;76(4):474-9. doi: 10.1038/bjc.1997.412.
4
Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome.上皮性卵巢癌中的谷胱甘肽S-转移酶活性：与化疗反应和疾病转归的关联
Ann Oncol. 1997 Apr;8(4):343-50. doi: 10.1023/a:1008247428385.
5
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics.乳腺癌：肿瘤组织中的预处理耐药参数（谷胱甘肽系统、芳香基硫酸酯酶、P-糖蛋白）及其与临床和预后特征的相关性。
Ann Oncol. 1997 Apr;8(4):335-41. doi: 10.1023/a:1008202723066.
6
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.卵巢癌患者中对化疗反应及DNA修复具有潜在重要性的基因表达
Gynecol Oncol. 1997 Apr;65(1):130-7. doi: 10.1006/gyno.1996.4609.
7
Apoptosis and the dilemma of cancer chemotherapy.细胞凋亡与癌症化疗的困境
Blood. 1997 Mar 15;89(6):1845-53.
8
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.氯乙基亚硝基脲和顺铂在O6-烷基鸟嘌呤-DNA烷基转移酶细胞浓度不同的人胶质瘤细胞系中诱导的DNA链间交联和细胞毒性。
Br J Cancer. 1997;75(4):500-5. doi: 10.1038/bjc.1997.87.
9
Characterization of a protein recognizing minor groove binders-damaged DNA.一种识别小沟结合剂损伤DNA的蛋白质的特性分析。
Nucleic Acids Res. 1996 Nov 1;24(21):4227-33. doi: 10.1093/nar/24.21.4227.
10
DNA repair: enzymatic mechanisms and relevance to drug response.DNA修复：酶促机制及其与药物反应的相关性。
J Natl Cancer Inst. 1996 Oct 2;88(19):1346-60. doi: 10.1093/jnci/88.19.1346.
Zotero 插件